Nieves Martinez Lago MD PhD

Thank you Colleagues for a phenomenal #ESMO26 ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME. 📣 101.7M impressions of potential reach 💬 6.1K posts on X from 988 participants in 34 countries ⚡ 43.1 posts per hour across the meeting days 😊 45% positive sentiment, with only 6% negative Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO 🏆 Top influencers @DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista 🌎 Where the conversation came from North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities. 🔬 Top studies by impact 1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts 2️⃣ VOLGA (bladder): 3.7M reach, 141 posts 3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach 4️⃣ SAFFRON (NSCLC): 3.3M reach 5️⃣ INTerpath-001 (melanoma): 154 posts Pinging our Collaborators

OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Risvutatug Rezetecan (Ris-Rez) Versus Gemcitabine and Docetaxel (GD) in Heavily Pretreated Patients With Relapsed or Refractory (R/R) Osteosarcoma: Primary Results From the Phase 3 ARTEMIS-011 Study 🦴 Phase 3 (n=122, China): B7-H3-directed ADC risvutatug rezetecan vs gemcitabine + docetaxel in R/R osteosarcoma after ≥2 prior lines; 25% adolescents. Primary endpoint: PFS by BICR. ➡️ Median PFS 5.5 vs 1.4 mo; HR 0.33; p<0.0001 ➡️ OS immature; HR 0.51 ➡️ Grade ≥3 TEAEs 92.5% vs 83.3%; treatment-related SAEs 63.8% vs 28.6% ✅ Significant PFS improvement with a favorable OS trend and manageable safety, highlighting potential as a new treatment standard for R/R osteosarcoma. 🎙️ Lu Xie (4Sight Made from Abstracts publicly available at the ESMO website)

As we inch closer to the wrap up of #ESMO26 🚨The Conversation is Buzzing Real-time congress metrics by AcuVox.io 📈 83.9M impressions 📝 5.2K posts from 884 voices in 32 countries 💬 50.9 posts/hour · 44% positive North America now leads the conversation, with Boston, London and New York the top cities!! These are the leading voices 👇but we thank everyone posting!! @OncoAlert @myESMO @DrChoueiri @NEJM @StephenVLiu @dr_yakupergun @PTarantinoMD @HHorinouchi @zklaassen_md @DrYukselUrun @tompowles1 @DraMartinezLago @ArndtVogel @adamfeuerstein Thank you for driving the conversation in Madrid! 🇪🇸 Pinging our faculty @cdanicas @hoperugo @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @DrSGraff @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @mzugman @HHorinouchi @p_ciracimd @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus

OncoAlert 4Sight Abstracts to be Presented at #ESMO26 A Randomized Trial of Paclitaxel ± Tovecimig in Previously Treated Patients With Advanced Biliary Tract Cancer @DrElkhoueiry @JavleMilind 🔬 Randomized phase 2/3 (n=168, 2:1): tovecimig (DLL4 × VEGF-A bispecific) + paclitaxel vs paclitaxel in previously treated advanced BTC. Primary endpoint: BICR ORR. ➡️ ORR 17.1% vs 5.3% (p=0.031); median PFS 4.7 vs 2.6 mo, HR 0.44 (p<0.0001) ➡️ OS HR 1.05 (p=0.78); 54% crossed over to tovecimig + paclitaxel ➡️ Related grade ≥3 hypertension 44%; TEAEs leading to discontinuation 40% vs 15% ✅ Significant ORR and PFS advantage; OS analysis confounded by high crossover, precluding a meaningful comparison. 🎙️ Nilofer Azad 👥 Zishuo Hu · Ilyas Sahin · Renuka Iyer · Olivia Aranha · Howard Hochster · Priyadarshini Pathak · Scott Paulson · Aparna Kalyan · Chih-Yi Liao · Nguyen Tran · Robin Kelley · Gregory Heestand · David Cosgrove · Anthony El-Khoueiry · Mitesh Borad · Nashat Gabrail · Umair Majeed · Lingling Du · Suneel Kamath · Nathan Shumway · Rachna Shroff · Lipika Goyal · Minori Rosales · Milind Javle (4Sight Made from Abstracts publicly available at the ESMO website) @CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, , @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,

The OncoAlert #ESMO26 PULSE Faculty is ready! 🇪🇸 WE ARE HERE! Meet our incredible faculty reporting live from Madrid: @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3 Whether you're at #ESMO26 in Madrid or following from home, our faculty will bring you the latest science, insights, and key updates straight from the congress. OncoAlert has you covered! Less noise. No nonsense. Just science. Strictly by colleagues, for colleagues!